Print page |
E-mail page
| 
Download PDF
|
Add to briefcase
« Previous Release | Next Release »
Charlottesville, Virginia. June 6, 2005 -- Adenosine Therapeutics, LLC announced today that its licensing partner, Bristol-Myers Squibb Medical Imaging, has initiated Phase III clinical trials for BMS068645 (also known as ATL146e), a selective A2a adenosine receptor agonist designed for use as a pharmacologic stress agent in cardiac perfusion imaging studies.
The results of the Phase II trials in patients undergoing cardiac catheterization assessed the appropriate dosing and tolerability of BMS068645. Results of the Phase III trials could be used as the basis for a new drug application to the FDA.
In April 2000, Adenosine Therapeutics granted a worldwide license to Bristol-Myers Squibb Medical Imaging covering the development and use of BMS068645 as a pharmacologic stress agent for use in cardiac perfusion imaging studies. Bristol-Myers Squibb Medical Imaging is conducting and funding all clinical trials in cardiac imaging and licensing select data back to Adenosine Therapeutics for use outside the cardiac imaging field.
Researchers believe that BMS068645 could represent an improvement over existing pharmacologic stress agents — used in cardiac perfusion imaging studies for the assessment of coronary artery disease for patients who are unable to exercise at the required levels. BMS068645 is designed to selectively stimulate the A2a adenosine receptor responsible for coronary vasodilation. Research to date suggests that this compound could potentially result in improved tolerability. BMS068645 is currently being investigated in clinical trials subject to a United States investigational new drug application.
“The success of the Phase II trials gives us further optimism about the potential use of BMS068645/ATL146e in cardiac perfusion imaging studies,” said Adenosine Therapeutics co-founder and Chief Executive Officer Robert S. Capon. “This milestone also moves Adenosine Therapeutics a step closer to developing this class of compounds for potential use in acute inflammatory conditions.”
About Adenosine
Therapeutics
Adenosine Therapeutics focuses on the discovery and development of novel
pharmaceutical products that target adenosine receptor subtypes. Candidates
for drug development are identified and screened using the company’s
state-of-the-art platform technology. The company was founded with the
goal of bringing new adenosine-receptor selective drugs into clinical
trials for a broad range of potential indications. These drug indications
include inflammatory indications, sepsis, heart attack, ischemia-reperfusion
injury, vascular injury, spinal cord injury, organ transplantation, COPD,
asthma, diabetes, inflammatory bowel disease, retinopathy, epilepsy, Parkinson’s
disease, and site-specific angiogenesis. For more information on Adenosine
Therapeutics, log on to www.adenrx.com.